Cutaneous nocardiosis occurring in the context of severe or disseminated disease represents a clinically urgent situation. Patients typically present with a more rapid course from onset to diagnosis and are commonly hospitalised, requiring prompt and structured antibiotic management.
Severe nocardiosis and disseminated nocardiosis are the defining features of this protocol. In contrast to mild or localised forms, severe disease carries a more rapid clinical trajectory and demands a different treatment approach from the outset.
Disseminated infection — where nocardiosis has spread beyond a single site — substantially influences both the choice of initial therapy and the duration of treatment.
In contrast, patients with severe nocardiosis are typically hospitalized and have a more rapid course from onset to diagnosis.
This is particularly crucial in severe forms of nocardiosis (eg, disseminated or progressive pulmonary infection), where 2 or 3 different agents are typically initiated empirically.
Antibiotics that most Nocardia isolates demonstrate susceptibility to include amikacin, imipenem, linezolid, and trimethoprim-sulfamethoxazole (TMP-SMX).
If combination therapy is started empirically, treatment can be narrowed to monotherapy, particularly if there are signs of clinical improvement.
Patients with localized pulmonary nocardiosis are traditionally treated for up to 6 months, while those with disseminated disease (particularly involving the CNS) are commonly treated for at least 12 months.
View source ↗